XML 15 R6.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Adoption of new accounting standard
Total Caladrius Biosciences, Inc. Stockholders' Equity
Total Caladrius Biosciences, Inc. Stockholders' Equity
Adoption of new accounting standard
Series B Convertible Preferred Stock
Common Stock
Additional Paid in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Accumulated Deficit
Adoption of new accounting standard
Treasury Stock
Non- Controlling Interest in Subsidiary
Beginning Balance (shares) at Dec. 31, 2018         10 9,866            
Beginning Balance at Dec. 31, 2018 $ 37,454 $ (62) $ 37,726 $ (62) $ 0 $ 10 $ 436,433 $ (32) $ (397,977) $ (62) $ (708) $ (272)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Net loss (14,399)   (14,405)           (14,405)     6
Unrealized gain (loss) on marketable securities 34   34         34        
Share-based compensation (in shares)           94            
Share-based compensation 917   917       917          
Net proceeds from issuance of common stock (in shares)           451            
Net proceeds from issuance of common stock 1,038   1,038       1,038          
Ending Balance (shares) at Sep. 30, 2019         10 10,411            
Ending Balance at Sep. 30, 2019 24,982   25,248   $ 0 $ 10 438,388 2 (412,444)   (708) (266)
Beginning Balance (shares) at Jun. 30, 2019         10 10,413            
Beginning Balance at Jun. 30, 2019 29,622   29,889   $ 0 $ 10 438,133 0 (407,546)   (708) (267)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Net loss (4,897)   (4,898)           (4,898)     1
Unrealized gain (loss) on marketable securities 2   2         2        
Share-based compensation (in shares)           (2)            
Share-based compensation 254   254       254          
Net proceeds from issuance of common stock (in shares)           0            
Net proceeds from issuance of common stock 1   1       1          
Ending Balance (shares) at Sep. 30, 2019         10 10,411            
Ending Balance at Sep. 30, 2019 24,982   25,248   $ 0 $ 10 438,388 2 (412,444)   (708) (266)
Beginning Balance (shares) at Dec. 31, 2019         10 10,529            
Beginning Balance at Dec. 31, 2019 20,553   20,816   $ 0 $ 11 438,911 2 (417,400)   (708) (263)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Net loss (2,709)   (2,719)           (2,719)     10
Unrealized gain (loss) on marketable securities (14)   (14)         (14)        
Share-based compensation (in shares)           81            
Share-based compensation 942   942       942          
Net proceeds from issuance of common stock (in shares)           8,797            
Net proceeds from issuance of common stock 18,715   18,715     $ 8 18,707          
Ending Balance (shares) at Sep. 30, 2020         10 19,407            
Ending Balance at Sep. 30, 2020 37,487   37,740   $ 0 $ 19 458,560 (12) (420,119)   (708) (253)
Beginning Balance (shares) at Jun. 30, 2020         10 15,585            
Beginning Balance at Jun. 30, 2020 33,556   33,811   $ 0 $ 16 449,302 (7) (414,792)   (708) (255)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Net loss (5,325)   (5,327)           (5,327)     2
Unrealized gain (loss) on marketable securities (5)   (5)         (5)        
Share-based compensation (in shares)           (25)            
Share-based compensation 229   229       229          
Net proceeds from issuance of common stock (in shares)           3,847            
Net proceeds from issuance of common stock 9,032   9,032     $ 3 9,029          
Ending Balance (shares) at Sep. 30, 2020         10 19,407            
Ending Balance at Sep. 30, 2020 $ 37,487   $ 37,740   $ 0 $ 19 $ 458,560 $ (12) $ (420,119)   $ (708) $ (253)